Tonix Pharmaceuticals Holding CORP 8-K filings

Tonix Pharmaceuticals announced robust second-quarter 2026 financial results, highlighted by a significant increase in TONMYA net sales and progress across its clinical development pipeline.

Tonix Pharmaceuticals announced positive minutes from a Type C FDA meeting, confirming alignment on the design for a Phase 2 field study of its TNX-4800 to prevent Lyme disease.

Tonix Pharmaceuticals Holding Corp. announced that its Chief Medical Officer, Dr. Gregory M. Sullivan, will retire effective August 20, 2026.

Tonix Pharmaceuticals announced a significant agreement with a pharmacy benefit manager, extending TONMYA coverage to approximately 9 million Medicare Part D beneficiaries starting January 1, 2027.

Tonix Pharmaceuticals has enrolled the first participant in its Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder.

Tonix Pharmaceuticals announced a new agreement with a group purchasing organization, expanding commercial coverage for its fibromyalgia drug TONMYA to approximately 52 million U.S. lives.

Tonix Pharmaceuticals announced the publication of Phase 1 clinical data for its investigational monoclonal antibody, TNX-1500, showing favorable safety and efficacy in blocking immune responses.

Tonix Pharmaceuticals presented positive Phase 1 data for TNX-4800, a monoclonal antibody aimed at preventing Lyme disease, showing favorable safety and long-lasting pharmacokinetic profiles.

Tonix Pharmaceuticals reports Q1 2026 revenue of $6.9 million and provides updates on its commercial and clinical pipeline.

Tonix Pharmaceuticals shareholders approved the 2026 Stock Incentive Plan and authorized a potential reverse stock split.

Tonix Pharmaceuticals announced a significant agreement with a group purchasing organization, expanding commercial payer coverage for its fibromyalgia treatment, TONMYA, to approximately 35 million U.S. lives.

Tonix Pharmaceuticals reports Q1 2026 revenue of $6.9 million and a net loss of $40.8 million.

Tonix Pharmaceuticals announced program updates and Phase 1 data for its Lyme disease prevention candidate, TNX-4800, with plans for a Phase 2 field study in 2027.

Tonix Pharmaceuticals announced preclinical updates on TNX-1700 and TNX-4700 at the AACR Annual Meeting 2026, highlighting potential in gastric cancer and broader immuno-oncology applications.

Tonix Pharmaceuticals announced positive Phase 1 data and outlined plans for a Phase 2 field study of its single-dose Lyme disease preventative, TNX-4800.

Tonix Pharmaceuticals announced the dosing of the first participant in a Phase 1 investigator-initiated study for TNX-1900, its intranasal potentiated oxytocin product candidate, to assess its potential for treating migraine and craniofacial pain.

Tonix Pharmaceuticals announced its full year and fourth quarter 2025 financial results, highlighting the commercial launch of TONMYA for fibromyalgia and advancements across its clinical pipeline.

Tonix Pharmaceuticals Holding Corp. announced its common stock has been approved for transfer from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective March 3, 2026.

Tonix Pharmaceuticals Holding Corp. announced preliminary financial results for the year ended December 31, 2025, showing increased revenue and a reduced net loss, alongside higher operating cash burn.

Tonix Pharmaceuticals announced a registered direct offering of common stock and pre-funded warrants, raising approximately $20.0 million in gross proceeds.

Tonix Pharmaceuticals announced program updates for its Phase 2/3-ready long-acting monoclonal antibody, TNX-4800, for seasonal prevention of Lyme disease, including plans to meet with the FDA in 2026.

Tonix Pharmaceuticals secured exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist with promising preclinical results for chronic neuropathic pain.

Tonix Pharmaceuticals Holding Corp. announced the appointment of Irina Ishak as General Counsel, effective December 8, 2025, to lead legal, corporate governance, and compliance functions.

Tonix Pharmaceuticals announced FDA clearance of its Investigational New Drug application for TNX-102 SL to treat major depressive disorder, paving the way for a Phase 2 study.

Tonix Pharmaceuticals Holding Corp. amended its sales agreement to increase the maximum aggregate offering price of shares issuable under its at-the-market facility from $150 million to $400 million.

Tonix Pharmaceuticals' Board of Directors approved an additional $25 million for its share repurchase program, increasing the total authorization to $35 million.

Tonix Pharmaceuticals announces the U.S. commercial availability of TONMYA, a first-in-class, non-opioid treatment for fibromyalgia, marking the first FDA-approved innovation in over 15 years.

Tonix Pharmaceuticals reported Q3 2025 financial results, highlighted by the FDA approval and upcoming launch of Tonmya for fibromyalgia, alongside pipeline advancements.

Tonix Pharmaceuticals reported a widened net loss of $32.0 million for Q3 2025, alongside increased revenue and a strengthened cash position to $190.1 million.

Tonix Pharmaceuticals announced the dosing of the first patient in an investigator-initiated FOCUS study evaluating intranasal oxytocin for arginine-vasopressin deficiency.